Institute for Clinical and Economic Review releases draft evidence report on esketamine for treatment-resistant depression

21 March 2019 - Public comment period now open until 17 April 2019; requests to make oral comment during public meeting ...

Read more →

Institute for Clinical and Economic Review appoints new members to each of its three independent evidence appraisal councils

18 March 2019 - New members bring expertise in broad range of perspectives, including patient advocacy, health policy, economics, and clinical ...

Read more →

On the use of list prices in drug pricing research

14 March 2019 - In the limitations section of this article, we discussed in detail that list prices do not capture ...

Read more →

Institute for Clinical and Economic Review publishes revised protocol for assessing unsupported price increases for prescription drugs

15 March 2019 - Through April 19, ICER is accepting public input on which additional price increases should be included ...

Read more →

Institute for Clinical and Economic Review releases draft evidence report on siponimod for treating secondary progressive multiple sclerosis

14 March 2019 - Public comment period now open until 10 April 2019; requests to make oral comment during public meeting ...

Read more →

Drug price watchdog ICER dives into Trump fueled pharma rebate debate

13 March 2019 - With public and political winds blowing in the same direction, significant reform of the complicated U.S. ...

Read more →

Institute for Clinical and Economic Review publishes white paper on alternative models for pharmaceutical rebates

12 March 2019 - Paper explores how reforming or eliminating rebates may affect drug pricing, patient access, and incentives for future ...

Read more →

Overview of cost-effectiveness analysis

11 March 2019 - Health care decision makers, including patients, clinicians, hospitals, private health systems, and public payers (eg, Medicare), are ...

Read more →

ICER’s assessment finds Spinraza and Zolgensma provide substantial health benefits for people with spinal muscular atrophy

22 February 2019 - Current pricing of Spinraza would require a substantial discount to meet traditional cost-effectiveness ranges; Zolgensma’s value-based price ...

Read more →

ICER to publish upcoming assessment on additive cardiovascular disease therapies

22 February 2019 - Report will be subject of Midwest CEPAC meeting in September; open input now being accepted until ...

Read more →

ICER publishes final new evidence update for alirocumab, a PCSK9 inhibitor for treating high cholesterol

15 February 2019 - Based on new analyses of published results of the ODYSSEY Outcomes trial, alirocumab would meet cost-effectiveness thresholds ...

Read more →

ICER launches international collaborative to develop new methods to guide value-based pricing of potential cures

23 January 2019 - NICE in the UK and CADTH in Canada among international agencies participating; public input on key methodological ...

Read more →

New whitepaper identifies limitations in using ICER’s “potential budget impact” work to guide private payer budget decisions

18 January 2019 - A new whitepaper authored by Bruce Pyenson and colleagues from Milliman explains why ICER potential budget ...

Read more →

ICER to assess whether the most significant prescription drug price increases are supported by new clinical evidence

17 January 2019 - Public comments on draft protocol will be accepted through 13 February 2019. ...

Read more →

ICER posts draft scoping document for the assessment of treatments for Duchenne muscular dystrophy

11 January 2019 - Document open to public comment until 1 February 2019. ...

Read more →